TMO Stock Analysis: Thermo Fisher Scientific | NYSE

Diagnostics & Research | NYSE, USA | Market Cap: 259.154m USD | 12M Return: 17.3% | US8835561023 | Charts, Fundamentals & Technical Analysis

Reagents, Analytical Instruments, Clinical Diagnostics, Biopharma Services
Total Rating 66
Safety 80
Buy Signal 0.43
Life Sciences Tools & Services
Sub-Industry Rotation: -13.3
Market Cap: 259B
Avg Turnover: 1.33B
Risk 3d forecast
Volatility32.8%
VaR 5th Pctl5.39%
VaR vs Median-0.21%
Reward TTM
Sharpe Ratio0.55
Rel. Str. IBD90.2
Rel. Str. Peer Group45 pctl
Character TTM
Beta0.547
Beta Downside0.524
Hurst Exponent0.526
Choppyness4.12%
Drawdowns 3y
Max DD37.28%
CAGR/Max DD0.31
CAGR/Mean DD0.91
EPS (Earnings per Share) EPS (Earnings per Share) of TMO over the last years for every Quarter: "2021-09": 5.76, "2021-12": 6.54, "2022-03": 7.25, "2022-06": 5.51, "2022-09": 5.08, "2022-12": 5.4, "2023-03": 5.03, "2023-06": 5.15, "2023-09": 5.69, "2023-12": 5.67, "2024-03": 5.11, "2024-06": 5.37, "2024-09": 5.28, "2024-12": 6.1, "2025-03": 5.15, "2025-06": 5.36, "2025-09": 5.79, "2025-12": 6.57, "2026-03": 5.44, "2026-06": 6.03, "2026-09": 6.68,
EPS CAGR: 4.58%
EPS Trend: 90.0%
Last SUE: 2.70
Qual. Beats: 5
Revenue Revenue of TMO over the last years for every Quarter: 2021-09: 9330, 2021-12: 10702, 2022-03: 11818, 2022-06: 10970, 2022-09: 10677, 2022-12: 11450, 2023-03: 10710, 2023-06: 10687, 2023-09: 10574, 2023-12: 10886, 2024-03: 10345, 2024-06: 10541, 2024-09: 10598, 2024-12: 11395, 2025-03: 10364, 2025-06: 10854, 2025-09: 11122, 2025-12: 12215, 2026-03: 11005, 2026-06: 11994, 2026-09: 12137,
Rev. CAGR: 3.78%
Rev. Trend: 89.8%
Last SUE: 1.72
Qual. Beats: 7

Warnings

Below Avwap Earnings

Tailwinds

Calm
Confidence

Seasonality 11.9 years of data, until 10/2026

Jan +3.7% 9
Feb -6.8% 14
Mar -0.4% 0
Apr -2.6% 14
May -0.2% 0
Jun -0.6% 4
Jul +8.1% 47
Aug -0.0% 0
Sep +0.0% 0
Oct +1.2% 14
Nov +0.5% 0
Dec -1.4% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: TMO Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is a U.S.-based life sciences company headquartered in Waltham, Massachusetts, founded in 1956 and publicly traded since 1978. The firm operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services, serving customers in pharmaceutical, biotechnology, academic, government, clinical, and industrial markets worldwide.

The Life Sciences Solutions segment supplies reagents, instruments, and consumables used in biological and medical research, drug and vaccine discovery and production, and infectious disease diagnostics. The Analytical Instruments segment offers instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and industrial research markets, as well as clinical laboratories.

The Specialty Diagnostics segment includes clinical diagnostics products, immunodiagnostic offerings for allergy, asthma, and autoimmune disease testing, microbiology products for pathogen detection, and transplant diagnostics such as human leukocyte antigen typing. The Laboratory Products and Biopharma Services segment provides laboratory and research products, safety market offerings, and pharma services and clinical research support.

Operating as a diversified tools and services provider within the Life Sciences Tools & Services sub-industry, Thermo Fisher combines instrumentation, consumables, and outsourced research services, a model that supports recurring revenue through repeat consumable purchases and long-term biopharma service contracts.

Headlines to Watch Out For
  • Biopharma services revenue grows on rising clinical trial demand
  • Analytical Instruments margin pressure from China research spending slowdown
  • Capital deployment through Patheon CDMO acquisitions expands pharma services footprint
Piotroski VR-10 (Strict) 7.0
Net Income: 7.08b TTM > 0 and > 6% of Revenue
FCF/TA: 0.07 > 0.02 and ΔFCF/TA 0.72 > 1.0
NWC/Revenue: 24.17% < 20% (prev 16.94%; Δ 7.23% < -1%)
CFO/TA 0.08 > 3% & CFO 9.32b > Net Income 7.08b
Net Debt (35.3b) to EBITDA (12.1b): 2.93 < 3
Current Ratio: 1.81 > 1.5 & < 3
Outstanding Shares: last quarter (371.0m) vs 12m ago -1.85% < -2%
Gross Margin: 41.44% > 18% (prev 40.48%; Δ 0.96% > 0.5%)
Asset Turnover: 43.59% > 50% (prev 42.45%; Δ 1.14% > 0%)
Interest Coverage Ratio: 5.83 > 6 (EBIT TTM 8.96b / Interest Expense TTM 1.54b)
Altman Z'' 4.00
A: 0.10 (Total Current Assets 25.6b - Total Current Liabilities 14.2b) / Total Assets 114b
B: 0.56 (Retained Earnings 63.7b / Total Assets 114b)
C: 0.08 (EBIT TTM 8.96b / Avg Total Assets 109b)
D: 0.92 (Book Value of Equity 54.8b / Total Liabilities 59.5b)
Altman-Z'' = 4.00 = AA
Beneish M -3.12
DSRI: 0.84 (Receivables 9.62b/10.5b, Revenue 47.4b/43.7b)
GMI: 0.98 (GM 40.48% / 41.44%)
AQI: 1.00 (AQ_t 0.68 / AQ_t-1 0.68)
SGI: 1.08 (Revenue 47.4b / 43.7b)
TATA: -0.02 (NI 7.08b - CFO 9.32b) / TA 114b)
Beneish M = -3.12 (Cap -4..+1) = AA
What is the price of TMO shares?

As of November 22, 2026, the stock is trading at USD 669.54 with a total of 2,360,550 shares traded. Over the past week, the price has changed by -4.38%, over one month by -2.59%, over three months by +6.77% and over the past year by +17.31%.

Current recommended Stop Loss: 645.20 (which is 3.6% or 1.3 ATR below the current price).

Is TMO a buy, sell or hold?

Thermo Fisher Scientific has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy TMO.

  • StrongBuy: 20
  • Buy: 3
  • Hold: 3
  • Sell: 1
  • StrongSell: 0

What are the forecasts/targets for the TMO price?
Analysts Target Price 756.5 13%
Thermo Fisher Scientific (TMO) - Fundamental Data Overview as of 22 November 2026
Market Cap USD = 259b (259b USD * 1.0 USD.USD)
P/E Trailing = 36.8903
P/E Forward = 25.7732
P/S = 5.473
P/B = 4.856
P/EG = 2.079
Revenue TTM = 47.4b USD
EBIT TTM = 8.96b USD
EBITDA TTM = 12.1b USD
Long Term Debt = 39.1b USD (from longTermDebt, last quarter)
Short Term Debt = 2.26b USD (from shortTermDebt, last quarter)
Debt = 41.4b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 35.3b USD (calculated: Debt 41.4b - CCE 6.06b)
Enterprise Value = 294b USD (259b + Debt 41.4b - CCE 6.06b)
Interest Coverage Ratio = 5.83 (Ebit TTM 8.96b / Interest Expense TTM 1.54b)
EV/FCF = 38.77x (Enterprise Value 294b / FCF TTM 7.60b)
FCF Yield = 2.58% (FCF TTM 7.60b / Enterprise Value 294b)
FCF Margin = 16.04% (FCF TTM 7.60b / Revenue TTM 47.4b)
Net Margin = 14.96% (Net Income TTM 7.08b / Revenue TTM 47.4b)
Gross Margin = 41.44% ((Revenue TTM 47.4b - Cost of Revenue TTM 27.7b) / Revenue TTM)
Gross Margin QoQ = 42.78% (prev 41.21%)
Tobins Q-Ratio = 2.58 (Enterprise Value 294b / Total Assets 114b)
Interest Expense / Debt = 3.72% (Interest Expense 1.54b / Debt 41.4b)
Taxrate = 9.43% (742.0m / 7.87b)
NOPAT = 8.12b (EBIT 8.96b * (1 - 9.43%))
Current Ratio = 1.81 (Total Current Assets 25.6b / Total Current Liabilities 14.2b)
Debt / Equity = 0.76 (Debt 41.4b / totalStockholderEquity, last quarter 54.8b)
Debt / EBITDA = 2.93 (Net Debt 35.3b / EBITDA 12.1b)
Debt / FCF = 4.65 (Net Debt 35.3b / FCF TTM 7.60b)
Total Stockholder Equity = 53.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.52% (Net Income 7.08b / Total Assets 114b)
RoE = 13.32% (Net Income TTM 7.08b / Total Stockholder Equity 53.2b)
RoCE = 9.71% (EBIT 8.96b / Capital Employed (Equity 53.2b + L.T.Debt 39.1b))
RoIC = 8.12% (NOPAT 8.12b / Invested Capital 100.0b)
WACC = 6.91% (E(259b)/V(301b) * Re(7.48%) + D(41.4b)/V(301b) * Rd(3.72%) * (1-Tc(0.09)))
Discount Rate = 7.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -96.84 | Cagr: -1.40%
[DCF] Terminal Value 77.97% ; FCFF base≈7.00b ; Y1≈8.03b ; Y5≈11.8b
[DCF] Fair Price = 384.5 (EV 178b - Net Debt 35.3b = Equity 142b / Shares 370.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 89.96 | EPS CAGR: 4.58% | SUE: 2.70 | # QB: 5
Revenue Correlation: 89.82 | Revenue CAGR: 3.78% | SUE: 1.72 | # QB: 7
EPS current Quarter (2027-03-31): EPS=6.05 | Chg30d=+1.20% | Revisions=+25% | Analysts=13
EPS current Year (2026-12-31): EPS=25.28 | Chg30d=+0.60% | Revisions=+81% | GrowthEPS=+10.5% | GrowthRev=+7.8%
EPS next Year (2027-12-31): EPS=27.78 | Chg30d=+0.85% | Revisions=+59% | GrowthEPS=+9.9% | GrowthRev=+5.3%
[Analyst] Revisions Ratio: +68% (up=49, down=8)